Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

ClinicalTrials.gov ID: NCT04387461

Public ClinicalTrials.gov record NCT04387461. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.

Study identification

NCT ID: NCT04387461
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: CG Oncology, Inc.; Industry
Enrollment: 35 participants

Conditions and interventions

Conditions

Non Muscle Invasive Bladder Cancer

Interventions

Biological · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 8, 2020 (Actual)
Primary completion: Mar 7, 2023 (Actual)
Completion: May 28, 2024 (Actual)
Last update posted: Sep 25, 2024

2020 – 2024

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of California - San Diego	La Jolla	California	92093	—
University of California - Irvine	Orange	California	92868	—
Moffitt Cancer Center	Tampa	Florida	33612	—
Northwestern University	Tampa	Florida	33612	—
Johns Hopkins Medical Institution	Baltimore	Maryland	21287	—
Chesapeake Urology	Hanover	Maryland	21076	—
Mayo Clinic - Rochester	Rochester	Minnesota	55902-9823	—
New York University	New York	New York	10003	—
SUNY Upstate Medical University	Syracuse	New York	13210	—
Ohio State University	Columbus	Ohio	43210	—
Keystone Urology Specialists	Lancaster	Pennsylvania	17604	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
Spokane Urology	Spokane	Washington	99202	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04387461, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 25, 2024 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04387461 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →